终末期心力衰竭：心脏移植和人工心脏的未来。

IF 3.2 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Presse Medicale Pub Date : 2023-10-26 DOI:10.1016/j.lpm.2023.104191

Karl Bounader , Erwan Flécher

{"title":"终末期心力衰竭：心脏移植和人工心脏的未来。","authors":"Karl Bounader , Erwan Flécher","doi":"10.1016/j.lpm.2023.104191","DOIUrl":null,"url":null,"abstract":"<div>In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged heart failure, as bridge to transplant or as definitive implantation in non-transplant candidates. Although clinical results do not overcome those of HTx, improvement in the new generation of devices may help to reach the equipoise between the two therapies.This review will go through the evolution, current status and perspectives of both therapeutics.</div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"End-stage heart failure: The future of heart transplant and artificial heart\",\"authors\":\"Karl Bounader , Erwan Flécher\",\"doi\":\"10.1016/j.lpm.2023.104191\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged heart failure, as bridge to transplant or as definitive implantation in non-transplant candidates. Although clinical results do not overcome those of HTx, improvement in the new generation of devices may help to reach the equipoise between the two therapies.This review will go through the evolution, current status and perspectives of both therapeutics.</div>\",\"PeriodicalId\":20530,\"journal\":{\"name\":\"Presse Medicale\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2023-10-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Presse Medicale\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0755498223000283\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Presse Medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0755498223000283","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

在过去的几十年里，心脏移植和LVAD的结果都显著改善。心脏移植仍然是治疗末期心力衰竭的黄金标准，并将持续多年。最相关的限制是缺乏移植物和长期免疫抑制治疗的效果，尽管免疫抑制管理取得了进展，但这些治疗涉及感染、癌症和代谢并发症。机械循环支持在治疗终末期心力衰竭方面具有不可替代的作用，可以作为移植的桥梁或非移植候选者的最终植入物。尽管临床结果并不能克服HTx，但新一代设备的改进可能有助于达到两种疗法之间的平衡。这篇综述将介绍这两种疗法的发展、现状和前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

End-stage heart failure: The future of heart transplant and artificial heart

In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged heart failure, as bridge to transplant or as definitive implantation in non-transplant candidates. Although clinical results do not overcome those of HTx, improvement in the new generation of devices may help to reach the equipoise between the two therapies.

This review will go through the evolution, current status and perspectives of both therapeutics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Presse Medicale 医学-医学：内科

自引率

3.70%

发文量

审稿时长

43 days

期刊介绍： Seule revue médicale "généraliste" de haut niveau, La Presse Médicale est l''équivalent francophone des grandes revues anglosaxonnes de publication et de formation continue. A raison d''un numéro par mois, La Presse Médicale vous offre une double approche éditoriale : - des publications originales (articles originaux, revues systématiques, cas cliniques) soumises à double expertise, portant sur les avancées médicales les plus récentes ; - une partie orientée vers la FMC, vous propose une mise à jour permanente et de haut niveau de vos connaissances, sous forme de dossiers thématiques et de mises au point dans les principales spécialités médicales, pour vous aider à optimiser votre formation.